Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non–small-cell lung cancer in the USA

BACKGROUND: Randomized phase III trials have established the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as first-line treatment for EGFR mutation-positive advanced non–small-cell lung cancer (EGFR Mut+ NSCLC). This retrospective cohort study examined the managemen...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:PLoS One
Hoofdauteurs: Li, Yulin, Appius, Anita, Pattipaka, Thirupathi, Feyereislova, Andrea, Cassidy, Adrian, Ganti, Apar Kishor
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Public Library of Science 2019
Onderwerpen:
Research Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6319739/
https://ncbi.nlm.nih.gov/pubmed/30608948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0209709
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items